It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Novo Links with H2 Inc. for Diabetes Treatment App
December 19, 2018
- Takeda, Alphabet's Health Unit Team Up on Japanese Parkinson’s Patient Research
December 19, 2018
- Adcetris Label Expansion Gets European Panel Nod: Takeda
December 18, 2018
- Hisamitsu Files Asenapine Transdermal Patch for Schizophrenia in US
December 18, 2018
- Eisai Grants to Eurofarma Exclusive Rights for Obesity Agent Lorcaserin in Brazil
December 18, 2018
- Efficacy of Fentos Tape for Cancer Pain in Opioid-Naïve Patients Confirmed in PIII Study: Hisamitsu
December 17, 2018
- Janssen Applies for Darzalex for Previously Untreated Multiple Myeloma Patients
December 17, 2018
- Gilead Files HIV Triplet Biktarvy in Japan, JT Pact Termination Set for Jan. 1
December 17, 2018
- Astellas Makes Full Inroads into I/O Arena with Potenza Buyout
December 17, 2018
- Lundbeck Japan to Quadruple Workforce by Next Summer, Eyes Vortioxetine Launch: Chief
December 14, 2018
- Astellas CEO Sees Cell Therapy Biz Model Established by “around 2030”
December 14, 2018
- ASKA to Review 5-Year Biz Plan after Hit by NHI Price Cut, Despite New Drug Launches
December 14, 2018
- Daiichi Sankyo Mulling Moving Up DS-8201 Filing to FY2019: Oncology Chief
December 13, 2018
- Ethical Drug Sales Up 2.0% in October: Crecon
December 13, 2018
- Otsuka’s US Subsidiary Pulls Plug on License Deal to Sumatriptan Nasal Spray for Acute Migraine
December 13, 2018
- Eisai, Takeda to Provide Compound Libraries to GARDP for Development of New Antibiotics
December 13, 2018
- Armed with 2 New Drugs, EA Pharma Looks to Raise Profile in Chronic Constipation Space
December 12, 2018
- Astellas FLT3 Inhibitor Xospata Now Available in US
December 12, 2018
- Daiichi Sankyo, Sarah Cannon Ink Cancer Collaboration, DS-7300 Trial to Get Underway in FY2019
December 12, 2018
- Ribomic Hooks Up with US Research Consortium on FGF Aptamer Therapeutics
December 12, 2018
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…